IASO Biotherapeutics ('IASO Bio'), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...

Ahmedabad: Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has ...

CDSCO revises guidelines for issuance of export NOC for unapproved, approved new drugs: Gireesh Babu, New Delhi Friday, May 9, 2025, 08:00 Hrs [IST] The Central Drugs Standard Con ...

Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product ...

Lupin's approved tablets, indicated for the treatment of HIV-1 infection, are bioequivalent to Merck Sharp & Dohme LLC’s ...

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced ...

Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have ...

Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...

The investigational transdermal delivery system, known as Xulane Lo, is designed to deliver 150mcg of norelgestromin and 17.5mcg of ethinyl estradiol per day.

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...